---
title: "Lysergide (DT120) in Generalized anxiety disorder: Efficacy and safety"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Efficacy and safety. Topics: Summary: phase 3 trials Voyage and Panorama, Summary: phase 2b trial MMED008, Summary: academic LSD trials, and Summary: safety across studies. 4 evidence topics quoted from 21 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary/efficacy-and-safety"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Efficacy and safety

<a id="heading-1.1.2"></a>

## 1.1.2 Lysergide Efficacy and Safety

<a id="topic-1.1.2-1"></a>

### Summary: phase 3 trials Voyage and Panorama

Voyage and Panorama are phase 3, multicenter, randomized, double-blind, placebo-controlled trials of a single dose of DT120 orally disintegrating tablet (ODT) in adults with generalized anxiety disorder. Each has a 12-week Part A followed by a 40-week extension (Part B) in which participants could receive open-label DT120 ODT. All phase 3 results come from company topline announcements, presentations, and filings and from a report of the Voyage topline results; one author states that adoption will depend on full peer-reviewed reporting of the Voyage and Panorama topline results.

Voyage randomized 214 participants 1:1 to DT120 ODT 100 µg (107) or placebo (107). The least squares (LS) mean change in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12 was -11.6 with DT120 and -6.2 with placebo, a difference of -5.4 points (p<0.0001; standardized effect size d=0.81). Panorama randomized 245 participants 2:1:2 to DT120 ODT 100 µg (96), DT120 ODT 50 µg (52), or placebo (97); the Week 12 change was -9.8 with 100 µg and -4.7 with placebo, a difference of -5.1 points (p<0.0001; d=0.64). The 50 µg arm was not designed or powered for statistical comparisons and had placebo-adjusted changes of -3.5 at Week 4 and -3.6 at Week 12. In both trials, each key secondary endpoint (Clinical Global Impression of Severity [CGI-S] change at Week 12 and Day 2, HAM-A change at Week 1) had a placebo-adjusted difference with p<0.0001. At Week 12, HAM-A response (improvement of 50% or more) occurred in 43% versus 16% of participants in Voyage and 32% versus 14% in Panorama, and remission (HAM-A of 7 or less) in 14% versus 4% and 15% versus 4%. In Panorama, 91% of participants given 50 µg and 95% given 100 µg correctly guessed assignment to drug. Part B results are interim analyses of partial data, with cutoffs of July 15, 2026 (Voyage) and August 11, 2026 (Panorama).

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder); [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder); [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf); [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf); [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm); [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf); [Cubała (2026)](https://pubmed.ncbi.nlm.nih.gov/42848417/)

<a id="topic-1.1.2-2"></a>

### Summary: phase 2b trial MMED008

MMED008 was a phase 2b dose-finding trial conducted at 22 outpatient psychiatric research sites in the US from August 2022 to August 2023; its results were published online in September 2025 and posted on ClinicalTrials.gov. Of 198 participants randomized to a single dose of lysergide capsules (25, 50, 100, or 200 µg) or placebo, 194 formed the full analysis set and 147 (74.2%) completed the study. Participants were tapered off anxiolytic and antidepressant treatments and received no study-related psychotherapy. In the primary MCP-Mod dose-response test of HAM-A change at Week 4, 5 of 6 candidate models exceeded the adjusted critical value of 2.032; LS mean differences from placebo were -5.0 points (95% CI, -9.6 to -0.4) with 100 µg and -6.0 points (95% CI, -9.8 to -2.0) with 200 µg, and the 25 µg (-1.2; 95% CI, -6.0 to 3.5) and 50 µg (-1.8; 95% CI, -7.6 to 4.0) groups did not reach statistical significance versus placebo. At Week 8 (key secondary), all 6 models exceeded the critical value of 2.041. A secondary analysis gave a Week 4 difference with 100 µg of -7.6 points (95% CI, -11.8 to -3.4; Cohen d = 0.88), the figure company announcements report, and a Week 12 difference of -7.7 points (95% CI, -12.6 to -2.8; P = .003); these secondary tests were not adjusted for multiple comparisons. At Week 12, HAM-A response occurred in 26 of 40 (65.0%), 25 of 40 (62.5%), and 12 of 39 (30.8%) participants given 100 µg, 200 µg, and placebo, and remission in 19 (47.5%), 18 (45.0%), and 8 (20.5%). Approximately 85% of participants correctly identified assignment to active treatment. The phase 3 trials use an ODT formulation in place of the phase 2b capsule.

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/); [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf); [ClinicalTrials.gov NCT05407064 results](https://clinicaltrials.gov/study/NCT05407064?tab=results); [MindMed APA presentation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/144/mindmed-presents-phase-2b-study-of-mm120-for-generalized-anxiety-disorder-gad-at-american-psychiatric-association-apa-annual-meeting-in-new-york); [MindMed Phase 2b topline results announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/131/mindmed-announces-positive-topline-results-from-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder); [MindMed JAMA publication announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/192/journal-of-the-american-medical-association-jama-publishes-results-from-first-ever-randomized-placebo-controlled-clinical-trial-assessing-the-dose-dependent-efficacy-of-mm120-lysergide-d-tartrate-lsd-in-generalized-anxiety-disorder-gad)

<a id="topic-1.1.2-3"></a>

### Summary: academic LSD trials

Two trials in Switzerland, sponsored by University Hospital Basel and by the Multidisciplinary Association for Psychedelic Studies, tested oral LSD, given with talk therapy or psychotherapy, in participants with anxiety, with or without a life-threatening illness. NCT03153579 was a two-center, double-blind, placebo-controlled, two-period, random-order crossover trial with two sessions of LSD 200 μg or placebo per period and study visits consisting of talk therapy; 46 participants enrolled and 42 were analyzed. The State-Trait Anxiety Inventory Global (STAI-G) score decreased more with LSD up to 16 weeks after treatment (LS mean difference in change from baseline -16.2 [SE 5.8]; 95% CI, -27.8 to -4.5; d = -1.18; p = .007). A 2022 company announcement of an oral presentation reported STAI-G response (reduction of 30% or more) in 13 of 20 participants (65%) given LSD and 2 of 22 (9%) given placebo (p=0.003). At an uncontrolled follow-up 12 months after the end-of-study visit, STAI-G change from baseline was -21.6 (95% CI, -32.7 to -10.4) in the LSD-first group and -16.5 (95% CI, -26.2 to -6.8) in the placebo-first group, 11 participants (33%) were in anxiety remission, and post hoc tests found no difference between participants with and without a formal GAD diagnosis (P = 0.35 and P = 0.65). The LDA1 pilot (NCT00920387) randomized 12 participants with anxiety associated with life-threatening diseases to LSD-assisted psychotherapy with LSD 200 μg (8) or an active placebo of LSD 20 μg (4), and analyzed 8 and 3. At 2 months, state anxiety decreased (p = 0.021; effect size 1.2) and trait anxiety showed a trend (p = 0.033; effect size 1.1); three of eight participants given 200 μg fell below the threshold of 40, and participants correctly guessed the dose in all 24 blinded sessions.

Source: [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/); [Holze et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11536188/); [MindMed Liechti and Holze anxiety trial announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/43/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders); [ClinicalTrials.gov NCT03153579](https://clinicaltrials.gov/study/NCT03153579); [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/); [ClinicalTrials.gov NCT00920387](https://clinicaltrials.gov/study/NCT00920387)

<a id="topic-1.1.2-4"></a>

### Summary: safety across studies

Adverse events in the phase 3 trials were collected under FDA psychedelic drug guidance, which includes expected effects characterized as positive, favorable, or neutral. In Voyage Part A, treatment-emergent adverse events (TEAEs) occurred in 106 of 107 participants (99%) given DT120 ODT 100 µg and 74 of 107 (69%) given placebo, and study drug-related TEAEs in 102 (95%) and 51 (48%); no DT120 event was severe, no DT120 participant had a serious adverse event (SAE) against 3 (3%) with placebo, and 1 DT120 participant (1%) discontinued for a TEAE. In Panorama Part A, TEAEs occurred in 91 of 96 (95%), 49 of 51 (96%), and 61 of 97 (63%) participants given 100 µg, 50 µg, and placebo; SAEs in 2 (2%), 1 (2%), and 1 (1%) were all deemed unrelated, and no TEAE led to discontinuation or death. The most common dosing-day TEAEs with 100 µg were illusion (75% in Voyage, 68% in Panorama), nausea (38%, 37%), euphoric mood (26%, 31%), and headache (24%, 24%). Neither trial reported suicidal or self-injurious behavior on the Columbia-Suicide Severity Rating Scale. As of September 14, 2026, 14 participants across all DT120 studies had a treatment-emergent SAE, 1 of them deemed treatment-related in Voyage Part B (rate approximately 1.45%); the sponsor stated that Part B safety data are expected to be shared in a future presentation. In the phase 2b trial, TEAEs occurred in 76.9% to 100% of lysergide groups and 56.4% of the placebo group, 98.5% of adverse events occurred on the dosing day, and the one SAE (a panic attack 97 days after dosing in the 50 µg group) was deemed unrelated. Across four DT120 studies, a safety analysis reported no treatment-related SAEs, hallucinogen persisting perception disorder, or deaths, and a thorough QT study did not show QT prolongation. In NCT03153579, 8 participants (19%) had transient, mild acute untoward effects and 1 (2%) a treatment-related SAE of acute transient anxiety; LDA1 reported no drug-related severe adverse events.

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf); [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm); [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf); [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf); [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf); [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/); [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf); [Holze et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36266118/); [Gasser et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4086777/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
